← Return to all swing-trade opportunities
EW — Oversold Bullish Reversal
Status: Invalidated
Scanner score: 30.0/100
Why this was flagged
EW was identified as a bullish technical setup based on the Oversold Bullish Reversal pattern. The scanner found a score of 30.0/100 using trend alignment, momentum, price action, volume, and risk-management rules. Monitor update: Latest stored daily low of 85.0000 reached or fell below stop loss 85.2454.
Trade framework
Position-sizing example
These examples use the distance between the reference entry and stop-loss. They do not account for commissions, slippage, taxes, overnight gaps, or your personal account size.
Exit plan
- Stop-loss: Exit if the stop-loss is reached. Do not move the stop farther away to avoid taking the planned loss.
- Target 1: Consider taking partial profit when Target 1 is reached and reducing risk on the remaining shares.
- Target 2 or trailing exit: Consider closing the remaining position at Target 2, or use a disciplined trailing stop only if the trend remains strong.
- Time exit: Reassess or close a trade that fails to progress within the suggested holding window.
Technical chart
Daily closing price with moving averages and planned trade levels. This chart is a screening aid, not a guarantee of future results.
$1,000 educational outcome examples
These examples use a $1,000 position and fractional shares at the midpoint of the entry zone. Actual results can differ because of market gaps, fills, spreads, commissions, taxes, slippage, and changing conditions.
Easy explanation for new investors
The computer scanner looked for a specific pattern called an "Oversold Bullish Reversal." This happens when a stock price drops a lot, often confusing traders. It may have fallen too far and could be ready to bounce back up. The scanner saw a green candlestick that covered the previous red one, signaling strength. Also, the RSI, a tool that measures speed and strength of moves, was at 31.79. This low number suggests the stock had been selling heavily, which might mean it is undervalued right now.
What the price plan means
The setup suggested buying between $86.77 and $87.25. The plan aimed for a first target price of nearly $89.82 and a second target near $91.34. To protect money, the plan set a "stop loss" at $85.25. This is a safety limit. If the price falls below this number, you exit to avoid further losses. The plan offered a reward-to-risk ratio of 2. This means for every $1 you risk losing, the plan aimed to gain $2 in profit. This is considered a good balance for traders.
What could make the idea fail
This idea is now marked as "invalidated." That means the plan failed its safety test. The scanner noted that the stock’s recent low price of $85.00 dropped below the stop loss limit of $85.25. When a stock breaks its stop loss, the original prediction is considered wrong. The trend is likely moving down, not up. The relative volume was also 0.84, which is lower than normal. Low volume means fewer people are trading, making it harder to predict direction.
Important reminder
Always remember that trading plans can break. A scanner finding is not a guarantee of success. Markets are complex. This stock’s plan is no longer valid because it hit its safety limit. Please do not use this old data. Always check the latest news and current prices before making any decisions. Learning to spot when a plan fails is just as important as finding when one works.
Recent news context
This automated review is separate from the technical score. It summarizes recent related articles and does not predict price movement.
Overall context: Caution (Moderate confidence)
Edwards Lifesciences reported strong Q2 earnings, exceeding estimates with $0.78 EPS and 13.6% revenue growth to $1.74 billion, while analysts maintain a Moderate Buy consensus with an average price target of $100.27. Institutional activity shows mixed signals: the California State Teachers Retirement System significantly increased its position, but other major holders like Van ECK Associates and NS Partners reduced stakes. Insider activity has been consistently negative over the past year. The stock recently underperformed the broader market, closing at $86.77, approximately 6.76% below its 52-week high, despite a recent oversold technical setup.
Potentially supportive context
- Q2 earnings exceeded analyst estimates with $0.78 EPS and revenue increased 13.6% year-over-year to $1.74 billion.
- The California State Teachers Retirement System significantly increased its stake, holding over 80 million shares valued at $7.32 billion.
- Analyst sentiment remains positive with a consensus Moderate Buy rating and an average price target of $100.27.
Risks and caution items
- The stock closed at $86.77, which is 6.76% below its 52-week high of $96.29, and recently underperformed broader market indices.
- Multiple institutional investors, including Van ECK Associates and NS Partners, reduced their stakes in the company during the second quarter.
- GuruFocus indicates a trend of 39 insider sells and no buys over the past year, suggesting cautious sentiment among sophisticated investors.
- Recent technical scores indicate an oversold condition, which may reflect short-term market uncertainty despite a bullish reversal setup.
Latest reviewed article: Sep 9, 2026 4:26 pm
Recent related articles
TriCo Bancshares (NASDAQ:TCBK) is gaining market attention due to stronger-than-expected quarterly earnings, despite a cautious outlook from analysts. The company, which operates through Tri Counties Bank, shows resilience in community banking, consistent dividend distribution, and significant institutional ownership. The article explores how…
California State Teachers Retirement System significantly increased its stake in Edwards Lifesciences Corporation (NYSE:EW) by 9,187.8% during the second quarter, now holding over 80 million shares valued at $7.32 billion. Other institutional investors also acquired substantial new stakes in the medical research…
Jupiter Topco LLC recently acquired 25,021 shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH), valued at approximately $2.16 million, according to its latest 13F filing. Other institutional investors have also adjusted their holdings in the medical equipment provider. Analysts have issued varied ratings…
Edwards Lifesciences Corp. (EW) stock fell 1.15% on Thursday, closing at $89.78, despite a strong day for the broader market with the S&P 500 and Dow Jones Industrial Average both rising over 1%. The company's shares are currently 6.76% below their 52-week…
Edwards Lifesciences (NYSE: EW) announced it will participate in the Deutsche Bank Healthcare Summit on Wednesday, September 16, 2026. Bernard Zovighian, CEO, and Doretta Mistras, CFO, will represent the company, with Zovighian scheduled to present at 10:00 a.m. ET. A live webcast…
UBS AM, a unit of UBS Asset Management Americas LLC, reduced its stake in Zimmer Biomet Holdings, Inc. by 0.9% in the second quarter, selling 12,667 shares but retaining 1.46 million shares valued at approximately $125.5 million. The medical equipment provider exceeded…
Intuitive Surgical (ISRG) is prioritizing aggressive investment in research and development (R&D) to ensure long-term growth, despite current macroeconomic challenges and competitive pressures. This strategy focuses on innovation, including AI/ML and robotics, to expand into new disease areas like GI, cardiac, and…
Edwards Lifesciences' SVP, Corporate Controller Andrew Dahl sold 544 shares of the company's stock on August 31, 2026. This transaction is part of a broader trend of insider selling at the company, with 39 insider sells and no buys over the past…
Important: Some returned articles may describe competitors, industry conditions, or related companies. Open the source before relying on an article.
Scanner confirmations
- RSI is near oversold territory with bullish candle confirmation.
- Bullish engulfing candle detected.